Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers—even in microscopic amounts. Their work, published in the journal Nano Today, suggests that this “liquid biopsy” test could spare many patients unnecessary treatment-related side effects, directing them instead to effective therapies that could prolong their lives.
Click here for original story, Noninvasive test can detect even trace elements of prostate cancer
Source: Phys.org